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Oxidative stress and inflammation are common features and
major mediators of atherosclerosis in end-stage renal disease
(ESRD). Available evidence for oxidative stress in ESRD is
indirect and based on accumulation of byproducts of
interactions of reactive oxygen species (ROS) with various
molecules. Inflammation is a major cause of oxidative stress.
To explore the direct link between oxidative stress and
inflammation in ESRD, we studied leukocyte integrin
expression and ROS production in 18 ESRD patients and
18 controls. ESRD patients showed elevated plasma
malondialdehyde (MDA) and increased superoxide and
hydrogen peroxide (H2O2) production by granulocytes and
monocytes before dialysis. Hemodialysis resulted in a further
rise in plasma MDA and H2O2 production by granulocytes
and monocytes. Surface expression of Mac-1 (CD11b and
CD18) on granulocytes and monocytes was significantly
increased (denoting cell activation) in ESRD patients.
Granularity of granulocytes was significantly reduced before
dialysis and declined further after dialysis. The magnitude of
ROS production by granulocytes and monocytes was directly
related with CD11b expression as well as plasma ferritin and
parathyroid hormone levels and was inversely related to
protein catabolic rate. Thus, this study provides direct
evidence of spontaneous leukocyte activation and increased
ROS generation (hence the link between oxidative stress and
inflammation) in ESRD patients.
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Oxidative stress is a common feature and a major cause of
cardiovascular and other complications of end-stage renal
disease (ESRD).1–5 Although the precise mechanisms of
oxidative stress and inflammation in ESRD have not been
definitely elucidated, a number of factors appear to be
involved. These include uremic toxins,1–4,6–8 rennin–angio-
tensin system,9–12 hypertension,2,9,11–15 underlying disease
(diabetes, autoimmune disease, etc.),16 infection,17 iron
overload,18,19 antioxidant deficiency,1,2,20–24 and dialysis
procedures25–29 among others.
The available evidence for presence of oxidative stress in
patients with ESRD is based largely on increased plasma
concentration of stable byproducts of interaction of reactive
oxygen species (ROS) with various molecules such as lipids/
lipoproteins,1–4,30–32 proteins,1,2,6,33–35 thiols,6,30,33,36,37 carbo-
hydrates,34,35,38 and nucleic acids.1,2,39 Although highly sugges-
tive, these findings represent indirect evidence for oxidative
stress in this population. The indirect evidence of oxidative
stress in patients with ESRD is frequently accompanied by
elevated levels of markers/mediators of inflamma-
tion.4,5,20,27,40,41 It is of note that oxidative stress and
inflammation are intimately inter-related as each recruits and
amplifies the other to create a vicious cycle. For instance,
oxidative stress can provoke inflammation by activating nuclear
transcription factor-kB (NF-kB) and consequent generation of
pro-inflammatory cytokines and chemokines.38,42–44 Produc-
tion and release of reactive oxygen, chlorine, and nitrogen
species by the activated immune cells, inherent to inflamma-
tion, in turn, promotes oxidative stress.4,12,43,45
As noted above, there is ample indirect evidence for
presence of oxidative stress and inflammation in patients
with ESRD. However, to our knowledge, production of ROS
has not been directly demonstrated in ESRD patients.
Therefore, the present study was designed to test the
hypothesis that circulating leukocytes participate in produc-
tion of ROS in the uremic patients. The study further sought
to examine the effect of hemodialysis on production of ROS
by circulating leukocytes.
RESULTS
General data
Data are summarized in Tables 1 and 2. As expected, the
ESRD group exhibited significant increases in serum
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concentrations of creatinine, urea nitrogen, inorganic
phosphorus, and parathyroid hormone. In contrast, blood
hemoglobin concentration and serum iron level were
significantly lower, whereas plasma ferritin concentration
was significantly higher in the ESRD group as compared with
the corresponding values found in the control group.
Granulocyte count was significantly higher whereas lympho-
cyte count was significantly lower in the ESRD patients than
those found in the controls. Finally, plasma malondialdehyde
(MDA) (Figure 1) was significantly elevated in ESRD
patients.
Integrin expression data
Data are illustrated in Figures 2 and 3. The blood samples
obtained from ESRD patients, before hemodialysis, demon-
strated a significant increase in surface expression of CD11b
and CD18 (Mac-1) in the circulating granulocytes and
monocytes. This was accompanied by a significant reduction
of the side-scattering properties of granulocytes in the pre-
dialysis blood samples pointing to their spontaneous
degranulation (Figure 4). In confirmation of earlier studies,
CD4þ lymphocyte count was reduced and CD4þ to
CD8þ T-cell ratio was depressed in ESRD patients.
Hemodialysis treatment resulted in a significant reduction
of CD11b and CD18 expressions in granulocytes and
monocytes, and of CD11a and CD18 expressions in CD4þ
T cells and CD8þ T cells (data not shown).
ROS generation data
Data are shown in Figure 5. Production of superoxide was
significantly increased in the granulocytes of ESRD patients
before dialysis and remained elevated in the blood samples
obtained after hemodialysis. Moreover, hydrogen peroxide
(H2O2) production by circulating granulocytes was signifi-
cantly increased in the blood samples obtained before dialysis
and rose further after dialysis. H2O2 production in the circul-
ating monocytes, CD4þ , and CD8þ cells was unchanged in
ESRD patients before hemodialysis but significantly increased
after hemodialysis (data not shown).
Table 1 | Biochemical parameters in normal control and
ESRD groups
Control (n=18) ESRD (n=18)
Urea nitrogen (mg/dl) 1370.8 7075.3*
Creatinine (mg/dl) 0.870.1 11.170.7*
Calcium (mg/dl) 9.370.2 9.270.22
Phosphorus (mg/dl) 3.370.16 5.570.3*
iPTH (pg/ml) 4073.55 313748*
Hemoglobin (g/dl) 13.870.3 11.770.34*
Ferritin (ng/ml) 31.875.1 275798*
Transferin saturation (%) 2372 28.72.79
Albumin (g/dl) 4.070.1 3.970.1
Cholesterol (mg/dl) 17077 13678*
Kt/V — 1.4570.16
nPCR (g/kg/day) — 1.1970.12
ESRD, end-stage renal disease; iPTH, intact PTH; nPCR, protein catabolic rate.
*Po0.05 compared to control group.
Table 2 | Leukocyte and differential counts in normal control
and ESRD groups
Test Controls Pre-dialysis Post-dialysis
Leukocytes (cells/mm3) 60267189 67107340* 61047286**
Neutrophils (cells/mm3) 33257184 42887330* 38857272**
Monocytes (cells/mm3) 418731 514741.66 408728.56**
Lymphocytes (cells/mm3) 18687119 14757102* 1338789**
CD4+/CD8+ 2.6170.34 1.8070.20* 2.3970.25**
ESRD, end-stage renal disease.
*Po0.05 compared to control.
**Po0.05 compared to pre-dialysis.
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Figure 1 | Plasma MDA level in the control group and ESRD
patients obtained before and after hemodialysis.
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Figure 2 | Integrin expression in circulating granulocyte
measured as fluorescence intensities of CD18 and CD11b.
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Correlations and multivariate analyses
A significant direct correlation was found between granulo-
cyte H2O2 production and plasma MDA concentration in the
study population. Similarly, leukocyte ROS production was
positively related to plasma ferritin, intact parathyroid
hormone, and inorganic phosphorus concentrations (Ta-
ble 3). Multivariate analysis identified protein catabolic rate
as an independent predictor of granulocyte H2O2 production
(P¼ 0.013, b¼0.65) and CD11b expression as an inde-
pendent predictor of leukocyte H2O2 and superoxide
productions (P¼ 0.040, b¼ 0.424 and P¼ 0.047, b¼ 0.295,
respectively).
DISCUSSION
The main finding of the present study was the direct
demonstration of increased ROS generation by circulating
granulocytes and monocytes in ESRD patients before dialysis
and their further rise immediately after hemodialysis. These
observations point to the contribution of circulating
leukocytes, particularly granulocytes and monocytes to the
pathogenesis of ESRD-induced oxidative stress and its
exacerbation by hemodialysis procedure. The magnitude of
ROS production by granulocytes and monocytes in the study
population was significantly related to plasma concentration
of lipid peroxidation product, MDA, which is commonly
used as an indirect marker of oxidative stress.1,2,10 These
observations support the role of oxidative stress as opposed
to the mere reduction of renal excretion of MDA as a cause of
its accumulation in the plasma of ESRD patients.
Integrins are a family of heterodimeric adhesion receptors
that are formed by covalent association of a- and b-subunits.
Each of the subunits consists of a trans-membrane glyco-
protein with a large extracellular domain. Integrins are
present in all cell types and are essential for cell adhesion (to
other cells and to extracellular matrix), cell migration, and
tissue organization. Leukocyte integrins are distinct from
other integrins in that they share the b2-subunit (CD 18)
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Figure 3 | Integrin expression in circulating monocytes measured
as fluorescence intensities of CD18 and CD11b.
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Figure 4 | Granularity of the circulating granulocyte in the control
and ESRD patients obtained before and after hemodialysis.
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Figure 5 | Production of superoxide and H2O2 in the circulating
granulocyte of the control and ESRD patients obtained before
and after hemodialysis.
Table 3 | Correlations between serum creatinine, MDA,
phosphorus, iPTH and ferritin with superoxide and
hydrogen peroxide in the circulating granulocytes
H2O2 Superoxide
r P-value r P-value
Phosphorus 0.35 0.06 0.45 0.009
iPTH 0.53 0.002 0.42 0.024
Ferritin 0.39 0.04 0.39 0.027
MDA 0.36 0.01 0.21 0.132
iPTH, intact PTH; MDA, malondialdehyde; PTH, parathyroid hormone; H2O2, hydro-
gen peroxide.
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which is not expressed in other cell type. Three different types
of leukocyte integrins have thus far been identified based on
the nature of their a-subunits. These include lymphocyte
function associated antigen-1 (LFA-1, CD11a/CD18), Mac-1
(CD11b/CD18), and CD11c/CD18. CD11c/CD18, also
known gp150/95, is expressed on granulocytes and mono-
cytes but its function is currently unknown. Mac-1 is
expressed on monocytes and binds intercellular adhesion
molecule-1, fibrinogen, as well as C3bi, a product of
complement activation. In the resting granulocytes, Mac-1
is stored within intracellular granules and is mobilized to the
membrane upon cell activation. LFA-1 is expressed on
lymphocytes and binds intercellular adhesion molecule-1,
intercellular adhesion molecule-2, and intercellular adhesion
molecule-3 and plays a key role in attachment of lymphocytes
to the antigen-presenting cells.
Increased ROS production by circulating granulocytes
and monocytes in the blood samples obtained before
hemodialysis was accompanied by a significant rise in surface
expression of Mac-1 on these leukocytes. As noted above,
activation of granulocytes and monocytes results in
migration of Mac-1 from the intracellular pools to the cell
surface. Thus increased surface expression of Mac-1 on the
circulating monocytes and macrophages in ESRD patients
denotes their spontaneous activation in vivo. Increased
surface expression of Mac-1 was coupled with a significant
reduction of the side-scattering properties of granulocytes
in the pre-dialysis blood samples of ESRD patients. This is
not surprising as surface expression of Mac-1 depends on
its mobilization from intracellular granules in response to
cell activation. Taken together, increased granulocyte/
monocyte Mac-1 expression and diminished granulo-
cyte granularity in the pre-dialysis blood samples point to
spontaneous activation of these leukocytes in ESRD patients
in vivo. Increased leukocyte ROS production and Mac-1
expression found in the blood specimens closely reflect
in vivo conditions at the given time points. This is
because blood samples employed in the present study were
processed immediately after being drown with minimal
manipulations.
It is of note that surface expression of integrins
paradoxically declined in the blood samples obtained shortly
after dialysis despite the persistent rise in ROS production.
This phenomenon does not signify a diminution of the
leukocyte activation state. Instead, it most likely reflects
integrin-mediated adhesion of the activated monocytes/
granulocytes to the vascular endothelium, dialyzer mem-
brane, and extracorporeal tubing system as well as shedding
or internalization of these proteins.
Oxidative stress and inflammation play a major role in the
pathogenesis of atherosclerosis and cardiovascular disease
which are exceedingly prevalent in the ESRD popula-
tion.1–4,7,13 This process is mediated by oxidative modifica-
tion of low-density lipoprotein and lipoprotein remnants
that are substrates for uptake by macrophages and their
transformation to foam cells. In addition, oxidative stress
causes endothelial cell activation, which leads to expression
of vascular adhesion molecules, monocyte chemoattractant
protein-1 and monocyte colony-stimulating factor.41,46,47
These events lead to adhesion of monocytes to the
endothelium and their penetration in the sub-endo-
thelial space followed by their proliferation, transformation
to foam cells, plaque formation, plaque rupture, and
thrombosis.4,41,47,48
In addition to producing ROS including superoxide and
H2O2, activated phagocytes release myeloperoxidase. Myelo-
peroxidase converts H2O2 to hypochlorous acid which is a
highly oxidant agent (H2O2þCl-HOCl). It is of note that
byproducts of myeloperoxidase-mediated reactions are
abundantly present in the atheromatous plaques and in the
plasma of ESRD patients.3,40 Spontaneous and dialysis-
induced activation of the circulating granulocytes in ESRD
patients shown here can account for accumulation of the
byproducts of myeloperoxidase-mediated events in this
population.
In conclusion, the study provides direct evidence of
spontaneous granulocyte/monocyte activation and ROS
generation in ESRD patients before hemodialysis and their
exacerbation immediately after dialysis. These observations
illustrate the intimate link between oxidative stress and
inflammation in this population.
MATERIALS AND METHODS
Patients
The study protocol was approved by Human Subjects Institutional
Review Board of the University of California Irvine and completed
with the assistance of the University of California General Clinical
Research Center.
Eighteen patients (seven men and 11 women, aged 4774 years)
with ESRD maintained on hemodialysis for a minimum of 3 months
were recruited for the study. The underlying cause of ESRD in the
study population included diabetic nephropathy in 11, chronic
glomerulonephritis in four, hypertensive nephrosclerosis in two, and
polycystic kidney disease in one patient. Dialysis blood access
consisted of arterio-venous fistula in 12 and polytetrafluoroethylene
grafts in six patients. None of the patients had indwelling catheters
and none had received intravenous iron preparations or antibiotics
during the 2 weeks preceding the study. Hemodialysis therapy was
performed thrice weekly using cellulose acetate dialyzers. Individuals
with evidence of acute or chronic infection, or acute intercurrent
illnesses were excluded. Medical history, systolic and diastolic blood
pressures (pre- and post-dialysis), body weight, interdialytic weight
change, routine monthly laboratory data and dialysis prescription
including dialyzer type, and medications were recorded. A group of
18 normal age-matched control subjects (seven men, 11 women,
aged 4772 years) served as controls. Control subjects exhibiting
acute or chronic infection, acute intercurrent illnesses, hypertension,
diabetes, malignancy, psychiatric disorders, or those requiring
chronic medications were excluded. On each occasion, after
informed consent was obtained, a brief medical history was taken
and blood sample was collected by venipuncture.
Blood collection
In all ESRD patients, whole blood was collected after canulation of
the vascular access was completed but before the initiation of
170 Kidney International (2007) 71, 167–172
o r i g i n a l a r t i c l e JW Yoon et al.: Oxidative stress and inflammation in chronic kidney disease
dialysis. A second blood sample was obtained within 3–5 min after
completion of dialysis treatment. All blood samples were obtained
using a needle and syringe, applying gentle aspiration to minimize
shear stress ex vivo. To avoid in vitro activation/modification, blood
samples were processed immediately without being manipulated.
Total leukocyte and differential counts were measured by the clinical
laboratory at UCI Medical Center.
Assay for generation of ROS
Production of ROS in peripheral blood was assessed by flow
cytometry using fluorescent probes and FACSort system (Becton-
Dickinson Inc., San Jose, CA, USA). Blood samples were diluted five
times in phosphate-buffered saline, and incubated with 0.1 mg/ml of
dihydroethidium for measurement of superoxide or 0.125 mg/ml of
dihydrorhodamine 123 for measurement of H2O2. The incubations
were carried out for 15 min at 371C. The blood cells incubated
without dihydroethidium or dihydrorhodamine 123 were used as
controls. Cells were precipitated by centrifugation and supernatant
was discarded. The cell pellets were re-suspended in 50 ml of
phosphate-buffered saline and incubated for 30 min at room
temperature with fluorescein isothiocyanate-conjugated anti-CD14
monoclonal antibody for monocytes and PerCP-conjugated anti-
CD4 or anti-CD8 monoclonal antibodies for T lymphocyte. The red
blood cells were then lysed by incubation with 2 ml of fluorescence-
activated cell sorter lysing solution for 10 min at room temperature.
The leukocytes were washed twice with phosphate-buffered saline,
re-suspended, fixed in 0.5 ml 1% paraformaldehyde and processed
by flow cytometry. Mean fluorescence intensity of fluorescence
channels 1 and 2 channels were used for dihydrorhodamine 123 and
dihydroethidium analyses, respectively.
Immunostaining
Expression of integrin molecules on the surface of peripheral blood
leukocytes was assessed by three-color flow cytometry using
fluorescein isothiocyanate-conjugated anti-CD11a (aL-subunit of
integrin LFA-1) monoclonal antibodies, anti-CD11b (aM-subunit
of integrin CR3) monoclonal antibodies, and anti-CD18 (integrin
b2-subunit) monoclonal antibodies. Whole blood (200 ml) was
incubated with 20 ml of each of the above antibodies for 20 min at
room temperature in a dark space. The cells were then incubated in
2 ml of fluorescence-activated cell sorter lysing solution (Becton-
Dickinson, San Jose, CA, USA) for 15 min to lyse red blood cells.
The leukocytes were subsequently separated by centrifugation and
washed twice with phosphate-buffered saline to remove erythrocyte
remnants. Leukocytes were then collected by centrifugation, re-
suspended, and fixed in 0.5 ml of 1% paraformaldehyde before
analysis by flow cytometry.
Flow cytometry
The cells were gated for lymphocytes, monocytes, and polymorpho-
nuclear leukocytes. Lymphocyte phenotyping was carried out by
three-color analysis using a FACSort flow cytometer and CellQuest
software (Becton-Dickinson, San Jose, CA, USA). For each sample,
data from 10 000 lymphocytes, 10 000 polymorphonuclear leuko-
cytes, and 5000 monocytes were collected and analyzed. Forward
and side scatters were used to gate and exclude cellular debris. FL3
channels (PerCP-conjugated Ab) were used for gating and analysis
of CD4þ and CD8þ T lymphocyte, whereas fluorescence channel
1 channels (fluorescein isothiocyanate-conjugated Ab) were used to
study monocytes. Integrin expressions were assessed as mean
fluorescence intensity in fluorescence channel 2 channel.
MDA assay
Plasma concentration of malondialdehyde (MDA) was measured by
HPLC as described in our previous studies.49
Data analysis
Relative proportion and calculated absolute data for CD4þ T
lymphocytes, CD8þ T lymphocytes, granulocytes, and monocytes
were analyzed with Student’s t-test, paired t-test, regression analysis,
and multivariate analysis as appropriate using SPSS 13.5 software
(Chicago, IL, USA). Data are expressed as mean7s.e.; P-values less
than 0.05 were considered significant.
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